Deep biology, translated into strategy.
Founder-led scientific strategy for biotech, spinout, and investor teams — anchored in metabolic disease, and built to turn mechanism, evidence, and market dynamics into clear development, biomarker, and positioning decisions.
How we think
Deep science only creates value once it is translated into a decision. Valdez BioStrategy works at that seam — reading the biology, grading the evidence, and ending in a defensible call.
Mechanism-aware
We read the biology, not just the headline.
Evidence-graded
We separate approved indications from trial findings and emerging frontiers, and label each clearly.
Decision-oriented
Every analysis is built to support a strategic decision, not produce a literature dump.
Who we help
Biotech founders
Preparing for fundraising, platform positioning, or strategic inflection points where the science needs to hold up under scrutiny.
Academic spinouts
Translating discoveries into investable stories, credible development plans, and clear scientific narratives.
Investors & BD teams
Needing independent scientific diligence, landscape analysis, or KOL-informed perspective on early-stage opportunities.
Medtech-adjacent teams
Working at the intersection of metabolic disease, clinical workflow, digital health, and physician adoption.
What we deliver
Strategic Scientific Memo
Hypothesis-driven analysis for board, investor, or internal decision-making — the signature deliverable, supported by diligence, landscape, KOL, narrative, spinout, and retainer services.
Metabolic disease is our center of gravity.
Our work is anchored in metabolic disease because it is where deep biology, clinical evidence, and strategic urgency now converge. We think across diabetes, obesity, incretin and islet biology, MASH/MASLD, chronic kidney disease, cardiometabolic organ protection, biomarkers, translational endpoints, and therapeutic positioning.
When a question reaches beyond metabolic disease, Valdez BioStrategy can draw on a focused advisory bench for adjacent scientific, behavioral, legal/commercial, and translational perspectives.
Explore metabolic strategy →Founder-led scientific strategy
Valdez BioStrategy is led by Ivan A. Valdez, PhD — a Harvard-trained biomedical scientist and former healthcare strategy consultant with deep experience in diabetes and metabolic disease research, translational science, and competitive landscape analysis.
Meet the founder →Specialized expertise, engaged by scope
Valdez BioStrategy is founder-led by Ivan A. Valdez, PhD. When a scoped question calls for complementary expertise, specialized advisors may contribute perspective across clinical strategy, commercialization, neuroscience, cancer biology, and biomedical science.
See the advisory bench →Have a scientific strategy question?
For confidential biotech, spinout, investor, or strategic diligence inquiries, start with a brief scoping conversation.
Request a confidential scoping callPrefer email? contact@valdezbiostrategy.com